These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26197852)

  • 21. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
    Damber JE; Tammela TL; Iversen P; Abrahamsson PA; Boccon-Gibod L; Olesen TK; van der Meulen E; Persson BE
    Urology; 2012 Jul; 80(1):174-80. PubMed ID: 22748873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of LHRH antagonist cetrorelix in crossover conditioned media from epithelial (BPH-1) and stromal (WPMY-1) prostate cells.
    Siejka A; Schally AV; Barabutis N
    Horm Metab Res; 2014 Jan; 46(1):21-6. PubMed ID: 23839655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gonadotropin-releasing hormone antagonist: A real advantage?
    Kimura T; Sasaki H; Akazawa K; Egawa S
    Urol Oncol; 2015 Jul; 33(7):322-8. PubMed ID: 26070474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protease-activated receptor-1 upregulates fibroblast growth factor 7 in stroma of benign prostatic hyperplasia.
    Wang W; Zhang X; Mize GJ; Takayama TK
    Prostate; 2008 Jul; 68(10):1064-75. PubMed ID: 18386288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
    Lopes RD; Higano CS; Slovin SF; Nelson AJ; Bigelow R; Sørensen PS; Melloni C; Goodman SG; Evans CP; Nilsson J; Bhatt DL; Clarke NW; Olesen TK; Doyle-Olsen BT; Kristensen H; Arney L; Roe MT; Alexander JH;
    Circulation; 2021 Oct; 144(16):1295-1307. PubMed ID: 34459214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis.
    Hosseini SA; Rajabi F; Akbari Sari A; Ayati M; Heidari S; Ghamary F
    Med J Islam Repub Iran; 2016; 30():317. PubMed ID: 27390687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model.
    Hopmans SN; Duivenvoorden WC; Werstuck GH; Klotz L; Pinthus JH
    Urol Oncol; 2014 Nov; 32(8):1126-34. PubMed ID: 25242517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma.
    Sánchez C; Clementi M; Benitez D; Contreras H; Huidobro C; Castellón E
    Prostate; 2005 Nov; 65(3):195-202. PubMed ID: 15948150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.
    Klotz L
    Expert Opin Drug Metab Toxicol; 2015; 11(11):1795-802. PubMed ID: 26513436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Degarelix acetate for the treatment of prostate cancer.
    Klotz L
    Drugs Today (Barc); 2009 Oct; 45(10):725-30. PubMed ID: 20069136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
    Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
    Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia.
    Cohen P; Peehl DM; Baker B; Liu F; Hintz RL; Rosenfeld RG
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1410-5. PubMed ID: 7525636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Degarelix for prostate cancer.
    Doehn C; Sommerauer M; Jocham D
    Expert Opin Investig Drugs; 2009 Jun; 18(6):851-60. PubMed ID: 19453267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.
    Castellón E; Clementi M; Hitschfeld C; Sánchez C; Benítez D; Sáenz L; Contreras H; Huidobro C
    Cancer Invest; 2006; 24(3):261-8. PubMed ID: 16809153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Three-year follow-up of 12 patients with prostate cancer treated with monthly degarelix in a phase II clinical trial].
    Hoshi S; Hayashi N; Yagi M; Ookubo T; Muto A; Sugano O; Numahata K; Bilim V; Hoshi K; Sasagawa I
    Gan To Kagaku Ryoho; 2014 Jan; 41(1):65-9. PubMed ID: 24423954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas.
    Clementi M; Sánchez C; Benitez DA; Contreras HR; Huidobro C; Cabezas J; Acevedo C; Castellón EA
    Prostate; 2009 Jul; 69(10):1025-33. PubMed ID: 19301301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide.
    Iversen P; Karup C; van der Meulen E; Tankó LB; Huhtaniemi I
    Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):184-90. PubMed ID: 21445092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
    Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
    Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.
    Smith MR; Klotz L; Persson BE; Olesen TK; Wilde AA
    J Urol; 2010 Dec; 184(6):2313-9. PubMed ID: 20952020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.